Zacks Research Issues Optimistic Outlook for STERIS Earnings

STERIS plc (NYSE:STE) – Stock analysts at Zacks Research upped their Q2 2027 earnings estimates for shares of STERIS in a research report issued to clients and investors on Wednesday, November 27th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.58 per share for the quarter, up from their previous estimate of $2.51. The consensus estimate for STERIS’s current full-year earnings is $9.15 per share.

A number of other analysts also recently weighed in on the stock. JMP Securities reissued a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a report on Monday, November 18th. Stephens reissued an “overweight” rating and issued a $260.00 price target on shares of STERIS in a report on Thursday, November 7th. KeyCorp increased their price target on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a report on Friday, November 8th. Finally, Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and increased their price target for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $253.00.

STERIS Price Performance

NYSE STE opened at $219.06 on Monday. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. The company has a fifty day simple moving average of $225.01 and a 200 day simple moving average of $228.23. The company has a market cap of $21.62 billion, a P/E ratio of 50.01 and a beta of 0.85. STERIS has a 1 year low of $195.47 and a 1 year high of $248.24.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.02. The business had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. STERIS’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.03 EPS.

Institutional Investors Weigh In On STERIS

A number of hedge funds have recently made changes to their positions in the company. West Coast Financial LLC increased its position in shares of STERIS by 2.8% during the 3rd quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock worth $398,000 after purchasing an additional 45 shares in the last quarter. Taylor Frigon Capital Management LLC increased its position in STERIS by 0.8% in the 2nd quarter. Taylor Frigon Capital Management LLC now owns 6,175 shares of the medical equipment provider’s stock valued at $1,356,000 after acquiring an additional 46 shares in the last quarter. SkyView Investment Advisors LLC increased its position in STERIS by 1.6% in the 3rd quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock valued at $765,000 after acquiring an additional 51 shares in the last quarter. Mather Group LLC. increased its position in STERIS by 7.6% in the 2nd quarter. Mather Group LLC. now owns 763 shares of the medical equipment provider’s stock valued at $172,000 after acquiring an additional 54 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in STERIS by 16.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 402 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 57 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Activity

In related news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares in the company, valued at $10,603,710. This trade represents a 35.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the sale, the senior vice president now owns 11,372 shares of the company’s stock, valued at $2,471,363.04. This trade represents a 12.88 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s dividend payout ratio is 52.05%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.